RT Journal Article
T1 Adipose mesenchymal stromal cells isolated from type 2 diabetic patients display reduced fibrinolytic activity.
A1 Acosta, Lourdes
A1 Hmadcha, Abdelkrim
A1 Escacena, Natalia
A1 Pérez-Camacho, Inmaculada
A1 de la Cuesta, Antonio
A1 Ruiz-Salmeron, Rafael
A1 Gauthier, Benoit R
A1 Soria, Bernat
K1 Tissue Plasminogen Activator
K1 Plasminogen Activator Inhibitor 1
K1 Células del Estroma Mesenquimatoso
K1 Diabetes Mellitus, Type 2
K1 Fibrinólisis
AB Stem cells have been successfully used for the treatment of critical limb ischemia (CLI). We conducted a clinical trial to determine the feasibility of using autologous adipose-derived mesenchymal stromal cells (AdMSCs) for the treatment of CLI. Unexpectedly, two diabetic patients developed peripheral microthrombosis. This adverse effect, which contrasts with the reported antithrombotic properties of MSCs, may stem from the diabetic environment that alters the fibrinolytic activity of AdMSCs, thereby increasing the probability of developing thrombosis. Here, we confirm this premise by demonstrating that diabetic AdMSCs cultured in the presence of blood sera expressed and released higher levels of plasminogen activator inhibitor type 1, reduced levels of tissue plasminogen activator, and lower d-dimer formation compared with nondiabetic AdMSCs. Thus, to establish an appropriate cell therapy for diabetic patients, we recommend including new preclinical safety tests, such as the d-dimer and/or the tissue plasminogen activator-to-plasminogen activator inhibitor type 1 ratio tests, to assess fibrinolytic activity of cells before implantation.
PB American Diabetes Association
SN 0012-1797
YR 2013
FD 2013-12
LK http://hdl.handle.net/10668/2263
UL http://hdl.handle.net/10668/2263
LA en
NO Acosta L, Hmadcha A, Escacena N, Pérez-Camacho I, de la Cuesta A, Ruiz-Salmeron R, et al. Adipose mesenchymal stromal cells isolated from type 2 diabetic patients display reduced fibrinolytic activity. Diabetes. 2013; 62(12):4266-9
NO Journal Article; Research Support, Non-U.S. Gov't;
DS RISalud
RD Apr 18, 2025